

We're hoping to discover something... the *real* you

## The Flex-V Study

We are conducting a clinical research study to test the safety and effectiveness of an investigational medication in patients with rheumatoid arthritis (RA) who were previously unsuccessfully treated with another medication called a tumor necrosis factor-alpha (TNF- $\alpha$ ) inhibitor.

**You may be able to participate in the Flex-V Study if you:**

- are 18 years of age or older
- have been diagnosed with RA for at least 6 months
- have symptoms of active RA such as painful, swollen, and tender joints
- were previously treated with at least one TNF- $\alpha$  inhibitor
- are currently receiving treatment with a disease-modifying anti-rheumatic drug (DMARD) for at least 8 weeks (12 weeks if you are taking methotrexate).

*If you are unsure which medication you are taking, please check with your doctor.*

The Flex-V Study will last for up to 76 weeks. You will continue to take your DMARD therapy as usual throughout the study. The study will require regular visits to the study center so that the study doctors and nurses can monitor your RA symptoms and general health.

Taking part in the Flex-V Study will provide new information that will add to the current knowledge about RA treatment, which may potentially help other patients in the future.



CSI Research, Inc.  
Suzi DeFiesta  
Research Administrator  
770-667-0220  
770-667-0227 Fax  
sdefiesta@csi-research.com